AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20647097 — intervention group
Group type: EXPERIMENTAL
Intervention: manual‐dynamic activation group (final rinse 17%EDTA/3%NaOCl + gutta‐percha agitation)
Number of subjects: 50
Study 20647097 — intervention group
Group type: EXPERIMENTAL
Intervention: sonic‐activation group (final rinse 17%EDTA/3%NaOCl + Endoactivator)
Number of subjects: 50
Study 20647097 — intervention group
Group type: COMPARATOR
Intervention: no‐activation group (final rinse with a 27‐gauge needle and 17% EDTA/3% NaOCl)
Number of subjects: 50
Study 18381469 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported CRC screening
Number of subjects: 1280
Study 16047874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide 10% and sulfur 5% cream with sunscreens
Number of subjects: 152
Study 16047874 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream
Number of subjects: 152
Study 11929578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 33
Study 9893155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day by subcutaneous injection for 5 consecutive days as six monthly courses for a total cumulative dose of 2.1 mg/kg
Number of subjects: 52
Study 9893155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8578259 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus placebo
Number of subjects: 142
Study 8578259 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 142
Study 2134648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and preoperative treatment of the neck area
Number of subjects: 0
Study 30367733 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft covered with cross‐linked collagen membrane left exposed
Number of subjects: 30
Study 30367733 — intervention group
Group type: COMPARATOR
Intervention: Allograft covered with non‐crosslinked collagen membrane with primary closure
Number of subjects: 30
Study 28651697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32% DHA/0.64% ARA
Number of subjects: 0
Study 28651697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.64% DHA/0.64% ARA
Number of subjects: 0
Study 28651697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96% DHA/0.64% ARA
Number of subjects: 0
Study 28651697 — intervention group
Group type: COMPARATOR
Intervention: 0.00% DHA/0.00% ARA
Number of subjects: 0
Study 25291977 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid HCV testing
Number of subjects: 0
Study 25291977 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid HCV and HIV testing
Number of subjects: 0
Study 25291977 — intervention group
Group type: COMPARATOR
Intervention: No testing
Number of subjects: 0
Study 25291977 — intervention group
Group type: COMPARATOR
Intervention: Off-site HCV testing referral
Number of subjects: 0
Study 23530672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist led workshops (4 weekly 1-hour workshops covering pharmacokinetics, pharmacodynamics, drug interactions, and toxicity)
Number of subjects: 148
Study 23530672 — intervention group
Group type: COMPARATOR
Intervention: Control group (without explicit pharmacotherapy curriculum)
Number of subjects: 148
Study 23530672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 23530672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 148
Study 23530672 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall student feedback
Number of subjects: 148
Study 21863028 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy
Number of subjects: 525
Study 21863028 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for focal prostatic ablation
Number of subjects: 525
Study 21863028 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical specimens analysis
Number of subjects: 525
Study 18042559 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural administration of ropivacaine 2 mg ml(‐1), sufentanil 0.5 microg ml(‐1), clonidine 3 microg ml(‐1), and S(+)‐ketamine 0.25 mg ml(‐1) before incision (Group 1)
Number of subjects: 30
Study 18042559 — intervention group
Group type: COMPARATOR
Intervention: Saline before operation, study solution started at the end of surgery (Group 2)
Number of subjects: 30
Study 16595217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 106
Study 16595217 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 106
Study 16595217 — intervention group
Group type: COMPARATOR
Intervention: IVF- group (IVF only)
Number of subjects: 106
Study 16595217 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF+ group (IVF and ICSI)
Number of subjects: 106
Study 12964892 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin 3.9 mg/day
Number of subjects: 0
Study 12964892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12964892 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 0
Study 12964892 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin or oral tolterodine
Number of subjects: 0
Study 10715641 — intervention group
Group type: EXPERIMENTAL
Intervention: JI bypass
Number of subjects: 18
Study 9189773 — intervention group
Group type: EXPERIMENTAL
Intervention: Video defecography interpretation by four independent observers
Number of subjects: 100
Study 9189773 — intervention group
Group type: EXPERIMENTAL
Intervention: Video defecography overall accuracy
Number of subjects: 100
Study 1300436 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (mean dose 110 mg) intravenously 30 min prior to contrast injection
Number of subjects: 18
Study 1300436 — intervention group
Group type: COMPARATOR
Intervention: Control group received fluids (mean 3 liters)
Number of subjects: 18
Study 2859728 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethyldiazepam (from clorazepate)
Number of subjects: 8
Study 2859728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31756267 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized anaerobic high‐intensity interval training plus online lifestyle coaching program
Number of subjects: 40
Study 31756267 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lifestyle coaching program only
Number of subjects: 40
Study 31756267 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 40
Study 29704641 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically raised plasma C-reactive protein (CRP)
Number of subjects: 259
Study 29704641 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically raised plasma C-reactive protein (CRP) in ApoE ε4 carriers
Number of subjects: 259
Study 29704641 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP (>3 mg/l ≤ 10 mg/l) as an isolated reading
Number of subjects: 259
Study 27273977 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet's stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 41
Study 27273977 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery (control group)
Number of subjects: 41
Study 24166468 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg daily)
Number of subjects: 0
Study 24166468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23176887 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (2 puffs of 100 μg)
Number of subjects: 13
Study 23176887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 20332357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 152
Study 20332357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 18342964 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR)
Number of subjects: 279
Study 18342964 — intervention group
Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF)
Number of subjects: 279
Study 18342964 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR) in oropharynx/oral cavity subset
Number of subjects: 279
Study 18342964 — intervention group
Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF) in oropharynx/oral cavity subset
Number of subjects: 279
Study 18342964 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR) in larynx subset
Number of subjects: 279
Study 18342964 — intervention group
Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF) in larynx subset
Number of subjects: 279
Study 16398044 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 91
Study 16398044 — intervention group
Group type: COMPARATOR
Intervention: Control (no radiofrequency ablation)
Number of subjects: 91
Study 12131282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg daily
Number of subjects: 8113
Study 12131282 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 8113
Study 10408550 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Avonex)
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with one or more TIAs in the past 6 months and carotid stenosis ≥70%
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with mild stroke within 6 months and carotid stenosis ≥70%
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with TIAs within the past 6 months and stenosis 50% to 69%
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with progressive stroke and a stenosis ≥70%
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with mild or moderate stroke in the past 6 months and a stenosis 50% to 69%
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy ipsilateral to TIAs and a stenosis ≥70% combined with required coronary artery bypass grafting
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >75% by linear diameter
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >60% as measured by diameter reduction (pending ACAS report)
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >75% in a high-risk patient/surgeon
Number of subjects: 0
Study 7805271 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with ulcerative lesions without hemodynamically significant stenosis
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with moderate stroke with stenosis <50%, not on aspirin
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with single TIA, <50% stenosis, not on aspirin
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for high-risk patients with multiple TIAs, not on aspirin, stenosis <50%
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for high-risk patients, mild or moderate stroke, stenosis <50%, not on aspirin
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with global ischemic symptoms with stenosis <50%
Number of subjects: 0
Study 7805271 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with acute dissection, asymptomatic on heparin
Number of subjects: 0
Study 1674825 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg orally twice daily for one week
Number of subjects: 20
Study 1674825 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 5 mg/ml inhaled
Number of subjects: 20
Study 1674825 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg/ml inhaled
Number of subjects: 20
Study 6170218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground white rice
Number of subjects: 4
Study 6170218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground brown rice
Number of subjects: 4
Study 6170218 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice
Number of subjects: 4
Study 6170218 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice
Number of subjects: 4
Study 30668423 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract mixture of Andrographis paniculata and Syzygium polyanthum at a dose of 900 mg/day for 8 weeks
Number of subjects: 54
Study 30668423 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 54
Study 28837015 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedicine services for 12 months
Number of subjects: 200
Study 28837015 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 200
Study 26790200 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Baihui, Sishencong, Shenting, Yintang, Hegu, Taichong) applied in the observation group
Number of subjects: 100
Study 26790200 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation training in the control group
Number of subjects: 100
Study 23125396 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+MRIGE
Number of subjects: 59
Study 23125396 — intervention group
Group type: COMPARATOR
Intervention: CR
Number of subjects: 59
Study 21288450 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal decoctions for warming meridians to nourish blood and cervical traction (treatment group)
Number of subjects: 63
Study 21288450 — intervention group
Group type: COMPARATOR
Intervention: Cervical traction (control group)
Number of subjects: 63
Study 19321576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient-fortified biscuits (including iron 6 mg, zinc 5.6 mg, iodine 35 microg, vitamin A 300 microg retinol equivalents) given 5 days/week for 4 months
Number of subjects: 510
Study 19321576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient-fortified biscuits
Number of subjects: 510
Study 19321576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient-fortified biscuits with Albendazole (400 mg)
Number of subjects: 510
Study 16213292 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of cyclosporine
Number of subjects: 15
Study 16213292 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosing of cyclosporine (control group)
Number of subjects: 15
Study 11826593 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 echocontrast agent (SonoVue) 0.3 mL
Number of subjects: 30
Study 11826593 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 echocontrast agent (SonoVue) 0.6 mL
Number of subjects: 30
Study 11826593 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 echocontrast agent (SonoVue) 1.2 mL
Number of subjects: 30
Study 11826593 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 echocontrast agent (SonoVue) 2.4 mL
Number of subjects: 30
Study 10084096 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg min‐1 propofol
Number of subjects: 40
Study 10084096 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg min‐1 propofol
Number of subjects: 40
Study 7725880 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane-diethyl-ether azeotrope (HE)
Number of subjects: 12
Study 7725880 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 12
Study 1706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 240 mg
Number of subjects: 100
Study 1706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 300 mg
Number of subjects: 100
Study 1706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 360 mg
Number of subjects: 100
Study 1706012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7455480 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in female blood donors
Number of subjects: 171
Study 7455480 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation in male blood donors
Number of subjects: 171
Study 30450721 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 83
Study 30450721 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears of sodium hyaluronate (SH)
Number of subjects: 83
Study 28590309 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflated airway (G1)
Number of subjects: 441
Study 28590309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-inflated cuff (G2)
Number of subjects: 441
Study 28590309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-inflated cuff with external lifting of the larynx (G3)
Number of subjects: 441
Study 28590309 — intervention group
Group type: COMPARATOR
Intervention: Deflated airway (G1) and Pre-inflated cuff (G2) combined
Number of subjects: 441
Study 26044067 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400)
Number of subjects: 606
Study 26044067 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg (EFV600)
Number of subjects: 606
Study 24124717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and propofol anesthesia
Number of subjects: 60
Study 24124717 — intervention group
Group type: COMPARATOR
Intervention: Propofol and remifentanil anesthesia
Number of subjects: 60
Study 21256786 — intervention group
Group type: COMPARATOR
Intervention: Standard oral hygiene with chlorhexidine (GS)
Number of subjects: 147
Study 21256786 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene with electric dental brush (GR)
Number of subjects: 147
Study 19616720 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision (n=474)
Number of subjects: 922
Study 19616720 — intervention group
Group type: COMPARATOR
Intervention: Circumcision delayed for 24 months (n=448)
Number of subjects: 922
Study 19616720 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 922
Study 19616720 — intervention group
Group type: COMPARATOR
Intervention: Circumcision delayed for 24 months
Number of subjects: 922
Study 17667888 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 500 mg
Number of subjects: 14
Study 17667888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15364766 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV plus PEEP (various settings)
Number of subjects: 36
Study 15364766 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of assistance
Number of subjects: 36
Study 15364766 — intervention group
Group type: COMPARATOR
Intervention: PSV plus PEEP
Number of subjects: 36
Study 11596685 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, multimedia CD‐ROM program
Number of subjects: 42
Study 11596685 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture with black and white overhead transparencies and an 18‐minute videotape
Number of subjects: 42
Study 9482351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream tobacco smoke (SS)
Number of subjects: 23
Study 9482351 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 23
Study 8076657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor), initiated within 24 hours from the onset of the infarct and continued for 6 months
Number of subjects: 6090
Study 8076657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6090
Study 2915238 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day cisplatin, doxorubicin, and cyclophosphamide (PAC-I) chemotherapy
Number of subjects: 56
Study 2915238 — intervention group
Group type: COMPARATOR
Intervention: Five-day PAC (PAC-V) chemotherapy
Number of subjects: 56
Study 2915238 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal stage III disease
Number of subjects: 56
Study 2915238 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal or stage IV disease
Number of subjects: 56
Study 2915238 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ascites at diagnosis
Number of subjects: 56
Study 2915238 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without ascites at diagnosis
Number of subjects: 56
Study 1228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic cannula, catheter changed every 48 hr
Number of subjects: 50
Study 1228414 — intervention group
Group type: COMPARATOR
Intervention: Plastic cannula, catheter changed only when necessary
Number of subjects: 50
Study 1228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal needle, catheter changed every 48 hr
Number of subjects: 50
Study 1228414 — intervention group
Group type: COMPARATOR
Intervention: Metal needle, catheter changed only when necessary
Number of subjects: 50
Study 1228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters in place for longer than 56 hr
Number of subjects: 50
Study 1228414 — intervention group
Group type: COMPARATOR
Intervention: Catheters in place for less than 56 hr
Number of subjects: 50
Study 31340252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Survey on Patient Safety Culture (HSOPS)
Number of subjects: 314
Study 31340252 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous year event reporting
Number of subjects: 314
Study 27696678 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation for 15 minutes daily for 90 days
Number of subjects: 37
Study 27696678 — intervention group
Group type: COMPARATOR
Intervention: Normal routine (control group)
Number of subjects: 37
Study 26656017 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioural therapy (CBT) for CSOs, delivered over 10 weeks with nine modules and therapist support via email and telephone.
Number of subjects: 150
Study 23302419 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard goniometry
Number of subjects: 24